Scientists at the Johns Hopkins Kimmel Cancer Center have used data from the whole genome sequencing of cancer patients to develop individualized blood tests they believe can help physicians tailor patients' treatments. The genome-based blood tests, believed to be the first of their kind, may be used to monitor tumor levels after therapy... »
Latest Story
Avosentan Reduces Urinary Protein Loss but May Cause Serious Side Effects, Says Study
The drug avosentan substantially reduces urinary protein loss in people with type 2 diabetes and kidney disease, but the drug causes serious side effects, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results... »
Rituxan Approved to Treat Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer. Rituxan, an anti-cancer drug, is intended for patients with CLL who are beginning chemotherapy for the first... »
Robotic Surgery Faster in Repairing Kidney Blockages
A comparison of two types of minimally invasive surgery to repair kidney blockages that prevent urine from draining normally to the bladder found that robot-assisted surgery was faster and... »
Natural Compound Sceptrin Reduces Cancer Cell Motility
Scientists have discovered that the natural compound sceptrin, which is found in marine sponges, reduces cancer cell motility (movement) and has very low toxicity. Metastasis is one of the... »
Elderly with Untreated Vision Problem More Likely to Develop Alzheimer’s
Elderly people with visual disorders that are left untreated are significantly more likely to develop Alzheimer’s disease -- the most common form of dementia, according to a University of... »